drugset / Trial / NCT07804901
Asciminib Frontline Risk Adapted
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.
Timeline
- Start
- 2027-01-01
- Primary completion
- 2030-12-31
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Asciminib | Unknown | 80 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 80 mg | — |